drugset / Trial / NCT02945241

Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project

NCT02945241

Phase 1 Completed 399 enrolled Mayo Clinic
Non-randomizedParallel-groupOpen-labelSupportive care

Summary

Determine if a cystatin C-inclusive vancomycin dosing algorithm improved target trough achievement compared to creatinine clearance-guided vancomycin therapy in critically ill patients.

Timeline

Start
2014-04
Primary completion
2015-06
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified Intravenous